ACET News and Press, Adicet Bio Inc.

2026-03-13 09:15:06 ET Guggenheim analyst issues BUY recommendation for ACET on March 13, 2026 11:59AM ET. The previous analyst recommendation was Buy. ACET was trading at $7.04 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current anal...

2026-03-12 16:52:09 ET More on Adicet Bio Adicet Bio announces one-for-16 reverse stock split Seeking Alpha’s Quant Rating on Adicet Bio Historical earnings data for Adicet Bio Financial information for Adicet Bio Read the full article on See...

Strong enrollment momentum in Phase 1 autoimmune program evaluating prulacabtagene leucel (prula-cel, formerly ADI-001); clinical update expected in 1H/2026 with an additional update in 2H/2026 Achieved regulatory alignment with the FDA enabling outpatient dosing of prula-cel for lupus ne...

EHang Holdings Limited (EH) is expected to report $-0.06 for Q4 2025 McEwen Inc. (MUX) is expected to report $0.25 for Q4 2025 Hannover Ruck SE ADR - Level I (HVRRY) is expected to report $1.03 for Q4 2025 VAALCO Energy Inc. (EGY) is expected to report $0.02 for Q4 2025 Full Truck...

2026-03-11 18:38:21 ET Adicet Bio, Inc. (ACET) - This analysis reviews how the stock price reacted during the last 12 earnings periods. The average open to high on the day of earnings was 2.77%. The average open to low on the day of earnings was -4.40%. The average open to close...

2026-03-11 18:33:22 ET Adicet Bio, Inc. (ACET) - Following Earnings Price Analysis was done using last 12 quarters historical earnings. Opening Gap Moves The historical opening gap move in ACET stock price following earnings has averaged ±1.70% , with a median of 1.64%. The...

Transportadora de Gas del Sur SA TGS (TGS) is expected to report $0.51 for Q4 2025 John Wiley & Sons Inc. (WLY) is expected to report $0.86 for Q3 2026 Foghorn Therapeutics Inc. (FHTX) is expected to report $-0.28 for Q4 2025 Costco Wholesale Corporation (COST) is expected to repo...

Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that Chen Schor, President and Chief Executive Officer, will present at the Guggenheim Emerging Outlook: B...

Successfully completed meeting with FDA to align on and enable outpatient dosing of systemic lupus erythematosus (SLE) and lupus nephritis (LN) patients with prulacabtagene leucel (prula-cel, formerly ADI-001) in ongoing and future clinical studies All seven cohorts now actively enrolling...

2025-12-26 08:38:16 ET More on Adicet Bio Seeking Alpha’s Quant Rating on Adicet Bio Historical earnings data for Adicet Bio Financial information for Adicet Bio Read the full article on Seeking Alpha For further details see: Adicet Bio ann...